Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 490 • 2013 ACR/ARHP Annual Meeting
Does Low Disease Activity At Six Months Predict Remission At 12 Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real–World Setting?
Philip Baer¹, William G. Bensen², Andrew Chow³, Rafat Y. Faraawi^4,5, Denis Choquette⁶, Isabelle Fortin⁷, John T. Kelsall⁸, Dalton E. Sholter⁹, Emmanouil Rampakakis^10,11, John S. Sampalis^10,11, Francois Nantel¹², Allen J. Lehman¹³, May Shawi¹⁴ and Susan M. Otawa¹³, ¹Private Practice, Scarborough, ON, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁷Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Remission is considered the treatment goal in the management of patients with rheumatoid arthritis (RA). The objective of this analysis was to determine if…
Abstract Number: 2064 • 2012 ACR/ARHP Annual Meeting
Regular Measure of Disease Activity During the Routine Care of Rheumatoid Arthritis Patients Involves Some Extra Work but Positive Results
Lissiane K. N. Guedes¹, Ana Cristina Medeiros Ribeiro², Karina Rossi Bonfiglioli³, Diogo Domiciano¹, Carolina Reither Vizioli¹, Gilmara Franco da Cunha¹, Andressa Silva Abreu¹, Filipi M. Mello¹, Ana Luiza de Aguiar Foelkel⁴, Celio R. Gonçalves¹ and Ieda Laurindo¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: According to treat to target recommendations the use of validated composite measures of disease activity, which include joint assessments, is needed in routine clinical…
Abstract Number: 113 • 2012 ACR/ARHP Annual Meeting
Power Doppler Signal Is Frequently Positive Among Patients with Rheumatoid Arthritis in Clinical Remission and Normal Serum Matrix Metalloproteinase-3 (MMP-3) Levels
Tadashi Okano¹, Tatsuya Koike², Masahiro Tada¹, Kenji Mamoto¹, Yuko Sugioka¹, Atsuko Kamiyama² and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Medical School, Osaka, Japan, ²Rheumatosurgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Serum matrix metalloproteinase-3 (MMP-3) is useful bio markers of synovitis associated with rheumatoid arthritis (RA). Ultrasonography (US) has recently become more popular as a…
Abstract Number: 1682 • 2012 ACR/ARHP Annual Meeting
Sustained Clinical Remission (Disease Activity Score 28 <2.6) Protects for Cardiovascular Disease in Rheumatoid Arthritis Patients
Elke.E.A. Arts¹, Jaap Fransen², Alfons A. den Broeder³, Calin Popa¹ and Piet L.C.M. van Riel¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation appears to be an independent risk factor for CVD in rheumatoid arthritis (RA), but there is no clear difference in CVD risk…
Abstract Number: 78 • 2012 ACR/ARHP Annual Meeting
Factors Influencing On the Discordance Between 2011 ACR/EULAR Criteria and Physician’s Clinical Judgment for Remission in Rheumatoid Arthritis Patients
Yoon-Kyoung Sung¹, Bo Young Yoon², Soo-Kyung Cho¹, Chan-Bum Choi¹, Dae-Hyun Yoo³, Jae-Bum Jun³, Tae-Hwan Kim³, Shin-Seok Lee⁴, Tae-Jong Kim⁵, Jisoo Lee⁶, Jung-Yoon Choe⁷, Sung-Hoon Park⁸, Seung-Jae Hong⁹, Yeon-Ah Lee⁹, Jinseok Kim¹⁰, Eun-Mi Koh¹¹, Hoon-Suk Cha¹¹, Jaejoon Lee¹¹, Won-Tae Chung¹², Sung Won Lee¹², Choong-Ki Lee¹³, Hye-Soon Lee¹⁴, Wan-Hee Yoo¹⁵, Young Mo Kang¹⁶ and Sang-Cheol Bae³, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Inje University Ilsan Paik Hospital, Goyang, South Korea, ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁵Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁶Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ⁷Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁸Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ¹⁰Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, ¹¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹²Rheumatology, Dong-A University Hospital, Busan, South Korea, ¹³Yeungnam University Hospital, Daegu, South Korea, ¹⁴Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁵Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ¹⁶Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Remission is a primary end point in the treatment of rheumatoid arthritis (RA). To ensure more uniform reporting of outcome measures, American College of…
Abstract Number: 1594 • 2012 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes After One Year of Remission Steered Combination Treatment in Patients with Early Rheumatoid and Undifferentiated Arthritis
L. Heimans¹, K.V.C. Wevers-de Boer¹, K. Visser¹, H.K. Ronday², M. van Oosterhout³, J. H. L. M. Van Groenendael⁴, A.J. Peeters⁵, G. Steup-Beekman⁶, G. Collee⁷, P.B.J Sonnaville⁸, B.A. Grillet⁹, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Netherlands, ⁷MCH, The Hague, Netherlands, ⁸Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate the 1 year clinical and radiological outcomes of remission steered therapy in early arthritis patients treated aiming at remission (DAS
Abstract Number: 80 • 2012 ACR/ARHP Annual Meeting
Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials
Chenglong Han¹, Edward Keystone², Roy Fleischmann³, Josef S. Smolen⁴, Paul Emery⁵, Mark C. Genovese⁶, Mittie K. Doyle⁷ and Elizabeth C. Hsia⁷, ¹Outcomes Research, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, ²Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ³Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁴Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁵Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶Division of Rheumatology, Stanford University, Palo Alto, CA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Remission by Boolean-based definition (all scores on the tender joint and swollen joint count, CRP (mg/dL), and patient global assessment ≤1) and by Simplified…
Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael H. Schiff², Michael E. Weinblatt³, Michael A. Maldonado⁴, Elena M. Massarotti⁵ and Yusuf Yazici⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology Division, University of Colorado, Denver, CO, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴Medical Strategy, Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶New York University, New York, NY
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
Abstract Number: 1328 • 2012 ACR/ARHP Annual Meeting
The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Yoshinobu Koyama¹, Kazunori Hase², Daisuke Hidaka², Shuji Nagano³, Toshiyuki Ota³ and Ayumi Uchino², ¹Division of Rheumatology, Okayama Red Cross General Hospital, Okayama, Japan, ²Iizuka Hospital, Iizuka, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose: Although data are conflicting with regard to the clinical utility of MTX polyglutamates (PGs) measurements as a predictor of the efficacy or toxicity in…
Abstract Number: 1301 • 2012 ACR/ARHP Annual Meeting
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Clifton O. Bingham III¹, Michael Weinblatt², Alan Mendelsohn³, Lilianne Kim⁴, Michael Mack⁵, Jiandong Lu⁵, Daniel Baker³ and Rene Westhovens⁶, ¹Department of Medicine, Johns Hopkins University, Baltimore, MD, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁶Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of…
Abstract Number: 481 • 2012 ACR/ARHP Annual Meeting
Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients
Jon T. Einarsson¹, Pierre Geborek², Tore Saxne³ and Meliha C. Kapetanovic⁴, ¹Dept of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Section of Rheumatology, Dept of Clinical Sciences Lund, Lund, Sweden
Background/Purpose: Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA) patients and DAS28 remission criteria are widely used, despite their limitations. The purpose…
Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting
Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis
Bjorn Svensson¹, Maria LE Andersson², Sidona-Valentina Bala³, Kristina Forslind⁴ and Ingiäld Hafström⁵, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Department of Health Sciences,, Lund University, Lund, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
Abstract Number: 2661 • 2012 ACR/ARHP Annual Meeting
Disease Activity Score 28-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable?
Roy Fleischmann¹, Désirée van der Heijde², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴, Lisa Marshall⁵ and Eustratios Bananis⁴, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: Frequently DAS28-CRP is utilized instead of DAS28-ESR to assess rheumatoid arthritis (RA) disease activity; however, values for remission and low disease activity (LDA) for…
Abstract Number: 392 • 2012 ACR/ARHP Annual Meeting
Analysis of Factors Impact On Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis)
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is an element of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). This definition has been reported to better…
Abstract Number: 2639 • 2012 ACR/ARHP Annual Meeting
Residual Disease Activity in Patients with Early Rheumatoid Arthritis Who Were Classified As Being in Remission According to 8 Different Descriptions: Post Hoc Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: No single gold standard for remission is available for rheumatoid arthritis (RA). All available descriptions, including 2 proposed by an ACR/EULAR committee, allow residual…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].